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ABSTRACT 
 
Background: 
Selenium deficiency has been implicated in the pathogenesis of many thyroid 
diseases, namely hypothyroidism, autoimmune thyroid disease (ATD), 
endemic cretinism and thyroid cancer. 
Objectives: 
The study is conducted to evaluate serum selenium status in hypo and 
hyperthyroid patients and to compare the pre and post treatment levels. 
Methods: 
This is a prospective hospital based case control study conducted in 
Khartoum Teaching Hospital (KTH) (September 2010 to February 2011). 
The studied subjects were divided into 3 groups. The 1st two groups were 
adult male and female patients diagnosed clinically and biochemically as 
having hypo or hyperthyroidism. The 3rd group was age and sex matched 
normal controls. 
Data about the disease were collected from patients through a questionnaire. 
Sera were tested for selenium by atomic absorption spectrophotometer 
AA6800 (Shimadzu), and for thyroid hormones (T3 and T4) and TSH using 
the principle of chemiluminescence by Elecsys 2010 (Roche).  
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Results: 
The studied subjects were 60 (40 cases and 20 controls).  The mean serum 
selenium level in the hypothyroid group of patients was 63.82 ppb (+26.2 SD), 
significantly low compared to controls (P value<0.05). 
It was found that the mean serum selenium level in the newly diagnosed 
hypothyroid cases was 30.54ppb (+24.68SD), significantly lower compared to 
those on thyroxine  replacement (74.71ppb +17.57SD)( P value>0.05).  
The mean serum TSH of the hypothyroid patients (20.06µu/ml) and of the 
hyperthyroid patients (2.36µu/ml) was inversely related to serum selenium. 
The relation was statistically significant (P value <0.05). 
The mean serum T4 of the hypothyroid group (5.9µg/dl) was inversely 
related to serum selenium. The relation was statistically significant (P 
value<0.05). 
Conclusion: 
This is the first study conducted in Sudan to explore selenium status in hypo 
and hyperthyroidism. Significantly low serum selenium levels in hypothyroid 
patients confirm the possible implication of selenium deficiency in the 
causation of hypothyroidism as reported in the literature. 
Controlling hypothyroidism with thyroxine replacement may have a possible 
role in improving selenium deficiency; still this finding needs further 
exploration through longitudinal studies. 
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Inverse relationships were found between: (serum selenium and serum TSH) 
and (serum selenium and serum T4) confirming the role of selenium in 
thyroid hormone metabolism. 
Further studies that determine the prevalence of autoimmune thyroid disease 
in Sudan and to specifically evaluate selenium status in autoimmune thyroid 
disease are more valuable and thus needed. 
 Protocols for introducing selenomethionine supplements to patients with 
autoimmune thyroid disease and monitoring the response by following the 
level of thyroid antibodies are needed.  
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  ﻣﺴﺘﺨﻠﺺ
  :  ﻣﻘﺪﻣﺔ
 اﻟﺬاﺗﻴﺔ اﻟﻤﻨﺎﻋﺔ اﻣﺮاض ، اﻟﺪرﻗﻴﺔ اﻟﻐﺪة ﺧﻤﻮل وهﻲ اﻟﺪرﻗﻴﺔ اﻟﻐﺪة اﻣﺮاض ﻣﻦ ﺑﻜﺜﻴﺮ اﻟﺴﻴﻠﻨﻴﻮم ﻧﻘﺺﻳﺮﺗﺒﻂ 
  .  واﻟﺘﻘﺰم اﻟﺪرﻗﻴﺔ اﻟﻐﺪة ﺳﺮﻃﺎن ،
  :  اﻟﺒﺤﺚ اهﺪاف
   واﻟﻨﺸﻄﺔ اﻟﺨﺎﻣﻠﺔ اﻟﺪرﻗﻴﺔ اﻟﻐﺪة ﻣﺮﺿﻰ ﻓﻲ ﺑﺎﻟﺪم اﻟﺴﻴﻠﻨﻴﻮم ﻣﻌﺪل دراﺳﺔ اﻟﻰ اﻟﺒﺤﺚ ﻳﻬﺪف
  .  اﻟﺪم ﻓﻲ ﻠﻨﻴﻮمﻴاﻟﺴ ﻣﺴﺘﻮى ﻋﻠﻰ  اﻟﻐﺪة ﻣﺮض  ﻋﻼج ﺗﺎﺛﻴﺮ ودراﺳﺔ
  :  اﻟﺒﺤﺚ ﻃﺮﻳﻘﺔ
 ﺳﻤﺒﺘﺮ ﻣﻦ اﻟﻔﺘﺮة ﻓﻲ اﻟﺘﻌﻠﻴﻤﻲ اﻟﺨﺮﻃﻮم ﺑﻤﺴﺘﺸﻔﻰ اﺟﺮاؤﻩ ﺗﻢ ، ﺿﺎﺑﻂ ﺣﺎﻟﺔ ﻣﺘﺎﺑﻌﺎ ﺑﺤﺜﺎ اﻟﺒﺤﺚ هﺬا ﻳﻌﺪ
  1102 ﻓﺒﺮاﻳﺮ ﺣﺘﻰ 0102
  :. ﻣﺠﻤﻮﻋﺎت ﺛﻼﺛﺔ اﻟﻰ اﻟﻤﺒﺤﻮﺛﻴﻦ ﻳﻨﻘﺴﻢ
 واﻟﻨﺸﻄﺔ اﻟﺨﺎﻣﻠﺔ اﻟﺪرﻗﻴﺔ اﻟﻐﺪة ﻣﺮﺿﻰ ﻣﻦ اﻟﻴﺎﻓﻌﻴﻦ واﻻﻧﺎث ﻟﺬآﻮرا ﺗﺘﻀﻤﻦ واﻟﺜﺎﻧﻴﺔ اﻻوﻟﻰ اﻟﻤﺠﻤﻮﻋﺔ
  .اﻟﺘﻮاﻟﻲ ﻋﻠﻰ
   .اﻻﻧﺎث و اﻟﺬآﻮر ﻣﻦ اﻟﺒﺎﻟﻐﻴﻦ اﻻﺻﺤﺎء ﺗﻤﺜﻞ اﻟﺜﺎﻟﺜﺔ اﻟﻤﺠﻤﻮﻋﺔ
  : ﻟﻠﻤﺒﺤﻮﺛﻴﻦ اﻟﺘﺎﻟﻲ اﺟﺮاء ﺗﻢ
   اﻻﺳﺘﺒﻴﺎن ﻃﺮﻳﻖ ﻋﻦ اﻟﻌﻼج وﻓﺘﺮة وﻧﻮع اﻟﻤﺮض ﻋﻦ اﻟﻼزﻣﺔ اﻟﻤﻌﻠﻮﻣﺎت اﺧﺬ •
  :  اﻟﺘﺎﻟﻴﺔ اﻟﻔﺤﻮﺻﺎت ﻟﻌﻤﻞ ﺮومﻴاﻟﺴ اﺳﺘﺨﻼص ﺛﻢ وﻣﻦ ﻟﻠﺪم ﻋﻴﻨﺎت اﺧﺬ •
    HST اﻟﻨﺨﺎﻣﻴﺔ اﻟﻐﺪة ﻟﻬﺮﻣﻮن ﺑﺎﻻﺿﺎﻓﺔ 4T , 3T اﻟﺪرﻗﻴﺔ اﻟﻐﺪة هﺮوﻣﻨﺎت ﻓﺤﺺ .1
 . ﻮمﻨﻴاﻟﺴﻴﻠ ﻣﻌﺪل ﻓﺤﺺ .2
  :  اﻟﺒﺤﺚ ﻧﺘﺎﺋﺞ
  .(  اﻻﺻﺤﺎء ﻣﻦ 02و ﻣﺮﻳﺾ04) ﻣﺒﺤﻮﺛﺎ 06 اﻟﺒﺤﺚ ﻳﺘﻀﻤﻦ
 اﻻﻧﺤﺮاف) 28.36 bpp هﻮ اﻟﺨﺎﻣﻠﺔ اﻟﺪرﻗﻴﺔ اﻟﻐﺪة ﻣﺮﺿﻰ ﻓﻲ اﻟﺴﻴﻠﻨﻴﻮم ﻣﺴﺘﻮى ﻣﺘﻮﺳﻂ ان وﺟﺪ •
  . ﺑﺎﻟﻀﻮاﺑﻂ ﻣﻘﺎرﻧﺔ ﻣﻠﺤﻮﻇﺎ اﻧﺨﻔﺎﺿﺎ هﺬا وﻳﻌﺘﺒﺮ(  2.62اﻟﻤﻌﻴﺎري
 bpp ط هﻮ  اﻟﻐﺪة ﻋﻼج ﺗﻘﻠﻮا اﻟﻠﺬﻳﻦ اﻟﺨﺎﻣﻠﺔ اﻟﺪرﻗﻴﺔ اﻟﻐﺪة ﻣﺮﺿﻰ ﻓﻲ اﻟﺴﻴﻠﻨﻴﻮم ﻣﺴﺘﻮى ﻣﺘﻮﺳﻂ •
 ﻣﺴﺘﻮى ﺑﻤﺘﻮﺳﻂ ﻣﻘﺎرﻧﺔ ﻣﻠﺤﻮﻇﺎ ارﺗﻔﺎﻋﺎ ﺮﺗﻔﻌﺎﻣ ﻳﻌﺪ وهﺬا 75.71(ىاﻟﻤﻌﻴﺎر اﻻﻧﺤﺮاف) 17.47
( 63.42اﻟﻤﻌﻴﺎري اﻻﻧﺤﺮاف( ) bpp 54.03) اﻟﻐﺪة ﻋﻼج ﻳﺘﻠﻘﻮا ﻟﻢ اﻟﺬﻳﻦ اﻟﻤﺮﺿﻰ ﻓﻲ اﻟﺴﻴﻠﻴﻨﻮم
  .
 XI
 
 & HST   وهﺮﻣﻮﻧﻲ اﻟﺪم ﻓﻲ ﻮمﻨﻴاﻟﺴﻴﻠ ﻣﺴﺘﻮى ﻣﺘﻮﺳﻂ ﺑﻴﻦ ﻣﻠﺤﻮﻇﺔ ﻋﻜﺴﻴﺔ ﻋﻼﻗﺔ هﻨﺎﻟﻚ ان وﺟﺪ •
   4T 
  :  اﻻﺳﺘﻨﺘﺎج
 اﻧﺨﻔﺎض اﻟﺪراﺳﺔ ﺑﻴﻨﺖ. اﻟﺪرﻗﻴﺔ اﻟﻐﺪة ﻣﺮﺿﻰ ﻓﻲ ﻮمﻨﻴاﻟﺴﻴﻠ ﻣﺴﺘﻮى ﻟﺒﺤﺚ اﻟﺴﻮدان ﻓﻲ دراﺳﺔأول  هﺬﻩ ﺗﻌﺪ
 ﻮمﻨﻴاﻟﺴﻴﻠ ﻣﺴﺘﻮى ﺑﻴﻦ ﻋﻜﺴﻴﺔ ﻋﻼﻗﺔ اوﺟﺪتو  اﻟﺨﺎﻣﻠﺔ اﻟﺪرﻗﻴﺔ اﻟﻐﺪة ﻣﺮﺿﻰ ﻓﻲ اﻟﺪم ﻓﻲ ﻮمﻨﻴاﻟﺴﻴﻠ ﻣﺴﺘﻮى
   . اﻟﺪرﻗﻴﺔ اﻟﻐﺪة هﺮﻣﻮﻧﺎت اﻳﺾ ﻓﻲ ﻮمﻴاﻟﺴﻴﻠﻨ دور ﻣﺆآﺪة 4T&HST وهﺮﻣﻮﻧﻲ اﻟﺪم ﻓﻲ
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  1. INTRODUCTION AND LITERATURE REVIEW 
1.1. Introduction 
1.1.1. Selenium’s protective powers for the thyroid: 
In March 2003 French researchers looked at the connection between selenium intake, 
size of the thyroid and its structure. What they found was that in women lower 
selenium levels were associated with increased thyroid volume (goiter) and finally 
they concluded that selenium may protect against both goiter and autoimmune thyroid 
disease. Patients with all forms of autoimmune thyroid disease are known to have low 
selenium levels. Whether low selenium contributes to the condition or is caused by 
thyroid dysfunction is uncertain. However, recent studies show that patients with 
Graves' disease using selenium and the antioxidant vitamins beta carotene and vitamin 
C along with the anti-thyroid drug methimazole showed a better response than 
patients using the anti-thyroid drug methimazole alone. Patients improving from or in 
remission from autoimmune thyroid disease have higher selenium levels compared to 
their initial levels at the time of diagnosis(1). 
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1.2. Literature review 
1.2.1. The thyroid 
1.2.1.1. Structure and development 
The thyroid is a brownish-red and highly vascular gland located anteriorly in the 
lower neck, extending from the level of the fifth cervical vertebra down to the first 
thoracic. The gland varies from an H to a U shape and is formed by 2 elongated lateral 
lobes with superior and inferior poles connected by a median isthmus (with an 
average height of 12-15 mm) overlying the second to fourth tracheal ring (2). 
Under the middle layer of deep cervical fascia, the thyroid has an inner true capsule, 
which is thin and adheres closely to the gland. Extensions of this capsule within the 
substance of the gland form numerous septae, which divide it into lobes and lobules. 
The lobules are composed of follicles; the structural units of the gland, consisting of a 
layer of simple epithelium enclosing a colloid-filled cavity. This colloid (pink on 
hematoxylin and eosin [H&E] stain) contains an iodinated glycoprotein, 
iodothyroglobulin, a precursor of thyroid hormones. Follicles vary in size, depending 
upon the degree of distention, and they are surrounded by dense plexuses of 
fenestrated capillaries, lymphatic vessels, and sympathetic nerves (2). 
1.2.1.2. Function of the thyroid: 
The thyroid gland secretes three hormones: thyroxin (T4) and triodothyronine (T3), 
both of which are iodinated derivatives of tyrosine, and calcitonin, a polypeptide 
hormone.T4 and T3 are produced by the follicular cells (principle cells) but calcitonin 
is produced by the Para follicular cells (c cells or clear cells) and has a minor role in 
calcium homeostasis (3). 
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1.2.1.3. Thyroid hormones 
There are two biologically active thyroid hormones: thyroxin (T4) and 3, 5, 3’-
triiodothyronine (T3). They are composed of a phenyl ring attached via an ether 
linkage to a tyrosine molecule. Both have two iodine atoms on their tyrosine (inner) 
ring. They differ in that T4 has two iodine atoms on its phenyl (outer) ring, whereas 
T3 has only one. The compound formed if an iodine atom is removed from the inner 
ring of T4 is 3, 3', 5'-triiodothyronine (reverse T3, rT3), which has no biological 
activity but may be found in significant concentrations in the sera of patients with the 
sick euothyroid syndrome (4). 
Thyroid hormone synthesis involve a number of specific enzyme catalyzed reactions, 
beginning with the uptake of iodide by the gland and culminating in the iodination of 
tyrosine residues in the protein thyroglobulin (3). 
1.2.1.3.1. Thyroid hormones synthesis 
Iodine intake: The normal European daily dietary intake of iodine is about 150 µg, of 
which approximately 125 µg is taken up by the thyroid gland and used for hormone 
synthesis. 
Iodine (as the iodide, I-) is relatively abundant in seawater, and seafood is a rich 
dietary source. Fruit and vegetables also contain significant concentrations of iodine, 
although the amount depends on the soil and growing region. Areas of iodine 
deficiency tend to be inland, at high altitude and isolated and daily iodine intake may 
be as low as 25 µg . 
The synthesis in the thyroid gland takes place in the following way: 
A. Dietary iodine is  reduced to iodide (I-) in the gut, absorbed and circulates as 
iodide (5). 
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B. Iodide trapping: 
The active uptake of iodide (I-) by the follicular cells involves an energy-requiring 
(ATPase-dependent) transport mechanism which allows I- to be taken up from 
capillary blood against both a concentration and an electrical gradient in exchange for 
Na+. This enables the thyroid gland to concentrate iodide 30–50 times that of the 
circulating concentration. Other ions such as bromide, chlorate or pertechnetate 
(though not fluoride) may also compete with I- for this uptake process and this has 
important clinical uses. For example perchlorate is employed clinically as a 
competitive inhibitor and is useful when studying the kinetics of thyroid hormone 
secretion, it is also used as a prophylactic measure to inhibit uptake of radioactive 
iodide in cases of contamination or ingestion. The pertechnetate is used in 
radioisotope scanning of the thyroid. Thiocyanate and selenothiocyanate (SeCN-) can 
also inhibit the thyroidal iodide pump by competitive inhibition. On a normal daily 
iodide intake the thyroid gland clears approximately 20 ml of plasma iodide per 
minute (5). 
In the follicular cell, iodide passes down its electrochemical gradient through the 
apical membrane and into the follicular colloid. Iodide is instantly oxidized – with 
hydrogen peroxide as oxidant - by a thyroid peroxidase to atomic or molecular iodine  
at the colloid surface of the apical membrane. Thiouracil and sulfonamides block this 
peroxidase. 
C. The rough endoplasmic reticulum synthesizes a large storage molecule called 
thyroglobulin. This compound is build up by a long peptide chain with tyrosine 
units and a carbohydrate unit completed by the Golgi apparatus. Iodide-free 
thyroglobulin is transported in vesicles to the apical membrane, where they fuse 
with the membrane and finally release thyroglobulin at the apical membrane. 
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D. At the apical membrane the oxidized iodide is attached to the tyrosine units (L- 
tyrosine) in thyroglobulin at one or two positions, forming the hormone 
precursors   mono- iodotyrosine (MIT) and di-iodotyrosine (DIT), respectively. 
This and the following reactions are dependent on thyroid peroxidase in the 
presence of hydrogen peroxide –both located at the apical membrane. As MIT 
couples to DIT it produces tri-iodothyronine (3, 5, 3`-T3), whereas two DIT 
molecules form tetra-iodothyronine (T4), or thyroxine. These two molecules are 
the two thyroid hormones. Small amounts of the inactive reverse T3 (3, 3`, 5`- 
T3) is also synthesized (5). 
E. Each thyroglobulin molecule contains up to 4 residues of T4 and zero to one T3. 
Thyroglobulin is retrieved back into the follicular cell as colloid droplets by 
pinocytosis. Pseudo pods engulf a pocket of colloid. These colloid droplets pass 
towards the basal membrane and fuse with lysosomes forming phagolysosomes. 
F. Lysosomal exopeptidases break the binding between thyroglobulin and T4 (or T3). 
Large quantities of T4 are released to the capillary blood. Only minor quantities 
of T3 are secreted from the thyroid gland. 
G. The proteolysis of thyroglobulin also releases MIT and DIT. These molecules are 
deiodinated by the enzyme deiodinase, whereby iodide can be reused into T4 or 
T3. Normally, only few intact thyroglobulin molecules leave the follicular cells.  
H. TSH stimulates almost all processes involved in thyroid hormone synthesis and 
secretion (4). 
1.2.1.3.2. Thyroid hormones in the circulation 
The normal plasma concentrations of T4 and T3 are 60-150 nmol/l and1.0-2.9 nmol/l 
respectively. Both hormones are extensively protein bound: some 99.98% of T4 
6 
 and 99.66% of T3 are bound principally to a specific thyroxine binding globulin 
(TBG) and to a lesser extent, to prealbumin and albumin.TBG is approximately one 
third saturated at normal concentrations of thyroid hormones. 
The major product of the thyroid gland is T4.Ten times less T3 is produced. Most T3 
(approximately 80%) being derived from T4 by deiodination in the peripheral tissues, 
so that T4 is essentially a prohormone. Only the free (unbound) hormones are 
physiologically active. Although the total T4 concentration is 50 times that of T3,the 
different extents to which these hormones are bound to protein mean that the free T4 
concentration is only 2 to 3 times that of free T3(3). 
Changes in the TBG concentration affect the total hormones concentration (not the 
free): 
Increased TBG (increases total T4 and T3 measurements) 
• Pregnancy 
• Newborn state 
• Chronic Active Hepatitis 
• Biliary Cirrhosis 
• Infection 
• Acute intermittent porphyria 
• Familial hyperthyroxinemia 
• Drugs 
• Oral Contraceptives 
• Estrogens 
• Tamoxifen  
• Methadone  
• Heroin 
7 
• Perphenazine 
Decreased TBG (reduces total T4 and T3 measurements) 
• Chronic Liver Disease  
• Obstructive Jaundice or Cirrhosis 
• Severe systemic illness 
• Active Acromegaly 
• Nephrotic Syndrome  
• Surgical Stress 
• Medications 
• Androgens 
• Salicylates 
• L-asparaginase 
• Large doses of glucocorticoids (Prednisone) (6). 
Kinetics: studies on the kinetics of release and metabolism of iodothyronine show 
that T3 has a shorter half life (about 1-3 days) than T4 (about 5-7days), and reverse 
T3 is cleared very rapidly, with a half life of about 5 hours. However, T3 is 10 times 
more potent than T4 (5). 
1.2.1.3.3. Thyroid hormones Peripheral metabolism:  
Although some T3 is produced in the thyroid, approximately 80-85 percent is 
generated outside the thyroid, primarily by conversion of T4 in the liver and kidneys. 
The pituitary and nervous system are capable of converting T4 to T3, so are not 
reliant on T3 produced in the liver or kidney. Within the liver and kidney, the enzyme 
responsible for peripheral production of T3 is a selenium-dependent enzyme called 5'-
deiodinase. This enzyme removes iodine from T4's outer phenolic ring (7). Peripheral 
deiodination can also result in the formation of reverse T3 (r T3) and account for 95 
8 
percent of all rT3 produced (small amounts are produced within the thyroid. The 
enzyme responsible for this conversion is 5-deiodinase and is not believed to be 
dependent on selenium for its activity. This enzyme acts on the nonphenolic ring of 
T4 (the inner tyrosyl ring) to produce the hormonally inactive rT3. Under normal 
conditions, 45-50 percent of the daily production of T4 is transformed into rT3. 
Substantial individual variation in these percentages can be found secondary to a 
range of environmental, lifestyle, and physiological influences. Production also 
increases in cases of starvation & in many non-thyroidal illnesses. Although an 
adequate understanding of the metabolic role of rT3 is somewhat limited, it is thought 
to be devoid of hormonal activity and to act as the major competitive inhibitor of T3 
activity at the cellular level. Experimental data also suggests rT3 has inhibitory 
activity on 5'-deiodinase. Suggesting it might also directly interfere with the 
generation of T3 from T4(7). 
Further degradation of rT3 and T3 results in the formation of several distinct 
diiodothyroxines: 3,5-diiodothyronine(3,5-T2), 3,3'-diiodothyronine(3,3'-T2), and 3', 
5'-diiodothyronine (3',5'-T2). The metabolic role of the T2 isomers is poorly 
understood and the absolute contribution of these hormones to physiological function 
in humans is unclear. 
A second pathway of thyroid hormone metabolism involves the conjugation of the 
phenolic hydroxyl group of the outer phenolic ring with sulfate or glucuronic acid. 
These conjugation reactions occur primarily in the liver, and to a lesser degree in the 
kidney, and result in biotransformation of T4 and T3. The resultant metabolites are 
primed for elimination and are considered relatively inactive. It is thought that 
partially deiodinated thyroid hormone metabolites are preferred substrates for these 
conjugation reactions. Thyroid hormones can also undergo deamination and 
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decarboxylase reactions in the liver, resulting in the formation of so-called acetic acid 
analogues.  These  reactions  occur  at the alanine side-chain of the inner tyrosyl ring. 
Although these  analogues  are thought to be metabolically active, little is known 
about the quantities produced or their contribution to hormone activity in animals or 
humans (7). 
1.2.1.3.4. Mechanism of action 
Thyroid hormones have many important biological effects. A major function is their 
control of the basal metabolic rate And calorigenesis through increased oxygen 
consumption in Tissue via the effects of thyroid hormone on membrane transport 
(Cycling of Nai/K+-ATPase with increased synthesis and Consumption of adenosine 
triphosphate) and enhanced mito-Chondrial metabolism (stimulation of mitochondrial 
respiration And oxidative phosphorylation). Thyroid hormones are known to stimulate 
neural development and normal Growth, promote sexual maturation, stimulate 
adrenergic Activity with increased heart rate and myocardial contractility, Stimulate 
protein synthesis and carbohydrate Metabolism, increase the synthesis and 
degradation of cholesterol and triglycerides, increase the requirement for vitamins, 
increase the calcium and phosphorus metabolism, and enhance the sensitivity of 
adrenergic receptors to catecholamines. These effects are typically magnified in 
patients with either an overactive thyroid gland, such as in hyperthyroidism or 
reduced in patients with a sluggish thyroid such as in hypothyroidism (8). 
1.2.1.3.5. Regulation of the thyroid gland 
Regulation of thyroid hormones occur from regions external to the gland (extra 
thyroidal pathway) and from within the thyroid itself (auto regulation). 
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1.2.1.3.5.1. Extra thyroidal pathway (hypothalamic-pituitary-thyroid axis) 
The activity of the thyroid gland is controlled by thyroid stimulating hormone (TSH) 
from the anterior pituitary, the secretion of this is controlled by thyrotrophin releasing 
hormone (TRH) from the hypothalamus.TSH stimulates the secretion and synthesis of 
thyroid hormones and these (mainly T3) suppress TSH secretion and modulate the 
response of the pituitary to TRH (-ve feed back mechanism). TSH production is also 
blunted by somatostatin, rising levels of glucocorticoids, sex hormones and 
excessively high blood iodine concentration (8) 
1.2.1.3.5.2. The effect of dietary iodide in hormone synthesis (autoregulation) 
The amount of iodine incorporated into thyroglobulin is directly related to the 
concentration of iodide reaching the thyroid gland from the circulation. Thus when 
dietary iodide is limited or deficient there will be little iodine incorporated into 
thyroglobulin, this will yield mainly MIT and few DIT residues in thyroglobulin and 
so,T3 is secreted in preference for T4, TSH secretion will increase and induces 
thyroid enlargement (endemic goiter).   
Under conditions of iodine sufficiency (dietary iodine intake >50 µg/day), a lot of 
DIT will be produced and thyroglobulin will contain more T4 than T3. 
Iodine excess: large doses of iodine will initially inhibit the synthesis and release of 
thyroid hormones, this paradoxical effect arises from inhibition of two intrathyroidal 
reactions; the adenylate cyclase response to the TSH & the organification of iodine 
(the Wolff-Chaikoff effect) (5). 
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1.2.1.4. Disorders of the thyroid 
1.2.1.4.1. Hypothyroidism: Hypothyroidism is defined as deficiency in thyroid 
hormone secretion and action; it is a common disorder that occurs in both mild and 
severe forms in 2% to 15% of the population (8). 
Women are afflicted more than men, and both sexes are affected more frequently with 
increasing age. Clinical symptoms vary from the obvious and easy to recognize 
lethargy, fatigue and cold intolerance to more subtle, subclinical disease with 
generalized symptoms that escape detection (9). 
Myxedema is a severe form of hypothyroidism in which there is accumulation of 
mucopoly saccharides in the skin and other tissues, leading to thickening of facial 
features and doughy induration of the skin (8). The term cretinism, used to define the 
severe impairment of physical and neurological development resulting from iodine 
deficiency during fetal and post-natal development, derived from ‘cretin’, a term first 
used in the Swiss Alps. The word cretin entered the vernacular as a term of abuse 
indicating severe mental retardation. In 1994, nearly 30% of the world population was 
at risk of iodine deficiency. The commitment from the World Health Organization in 
1990 to eliminate iodine deficiency disorders by the year 2000 (with a policy of 
iodide supplementation of salt) had reduced the population at risk to less than 15% by 
1997 (5). Symptoms of hypothyroidism include cold intolerance, weight gain, 
menstrual disturbances and impaired fertility, par aesthesia and fatigue. Physical signs 
include pallor, dull coarse facial features, hoarseness, bradycardia, and hyporeflexia(9).  
Metabolic abnormalities associated with hypothyroidism include anemia, dilutional 
hyponatremia, hyperlipidemia, and reversible increase in creatinine. 
Worldwide, iodine deficiency remains the foremost cause of hypothyroidism. In the 
United States and other areas of adequate iodine intake, autoimmune thyroid disease 
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is most common. The prevalence of antibodies is higher in women, and increases with 
age (9). 
1.2.1.4.1.1. Primary hypothyroidism 
Autoimmune: The most frequent cause of acquired hypothyroidism is autoimmune 
thyroiditis (Hashimoto thyroiditis), it is a histologic diagnosis first described by 
Hakaru Hashimoto, a Japanese surgeon working in Berlin. The incidence of 
Hashimoto's thyroiditis seen in practice is unknown but is roughly equal to that of 
Graves' disease (on the order of 0.3 - 1.5 cases per 1,000 population per year). The 
disease is 15 - 20 times as frequent in women as in men. It occurs especially during 
the decades from 30 to 50, but may be seen in any age group, including children. The 
body recognizes the thyroid antigens as foreign, and a chronic immune reaction 
ensues, resulting in lymphocytic infiltration of the gland and progressive destruction 
of functional thyroid tissue. Up to 95% of affected individuals have circulating 
antibodies to thyroid tissue. Antimicrosomal or antithyroid peroxidase (anti-TPO) 
antibodies are found more commonly than antithyroglobulin antibodies(95%vs60%). 
These antibodies may not be present early in the disease process and usually 
disappear over time (8). Hashimoto's thyroiditis is reported to occur in two varieties, an 
atrophic variety, perhaps associated with HLA-DR3 gene inheritance, and a goitrous 
form associated with HLA-DR5. Concerning susceptibility genes for Hashimoto's 
thyroiditis, non-MHC class II genes have been recently investigated. Regarding 
environmental factors, high iodine intake, selenium deficiency, pollutants such as 
tobacco smoke, infectious diseases such as chronic hepatitis C, and certain drugs are 
implicated in the development of autoimmune thyroiditis. The disease usually begins 
as gradual enlargement of the gland with gradual development of hypothyroidism 
(subclinical to overt hypothyroidism and may progress to myxoedema).  
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Occasionally the course may be marked by alternating hyper & hypothyroidism. 
Pregnant  ladies  with  Hashimoto,s  may  develop  post partum painless 
thyrotoxicosis (10). 
Hashimoto's thyroiditis and hypothyroidism are associated with Addison's disease, 
diabetes mellitus, hypogonadism, hypopara-thyroidism, and pernicious anemia. Such 
combinations are described as the polyglandular failure syndrome (10). 
Other causes of hypothyroidism include postpartum thyroiditis, subacute 
granulomatous thyroidits, drugs like amiodarone and lithium, post thyroidectomy, 
post radioactive iodine, following external neck irradiation, rare inborn errors of 
thyroid hormones metabolism (10). 
1.2.1.4.1.2. Central hypothyroidism 
Central hypothyroidism (secondary or tertiary) results when the hypothalamic-
pituitary axis is damaged. Various causes should be considered: 
• Pituitary adenoma 
• Tumors impinging on the hypothalamus 
• History of brain irradiation 
• Drugs (eg, dopamine, lithium) 
• Sheehan syndrome 
• Genetic disorders  
1.2.1.4.2. Laboratory Studies 
Third-generation TSH assays are readily available and are generally the most 
sensitive screening tool for primary hypothyroidism. The generally accepted reference 
range for normal serum TSH is 0.40-4.2 mIU/L. In NHANES III (1988-1994), 
 of 17,353 people evaluated, 80.8% had a serum TSH below 2.5 mIU/L; TSH 
concentrations rose with advancing age. TSH levels peak in the evening and are 
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lowest in the afternoon, with marked variations due to physiologic conditions such as 
illness, psychiatric disorders, and low energy intake. If TSH levels are above the 
reference range, the next step would be to measure total T4 with a measure of binding 
proteins. The levels of these binding proteins can vary by hormonal status, 
inheritance, and in various disease states. Hence, free T4 assays are becoming popular 
as they measure unbound (i.e., free hormone). However, free T4 assays can be 
unreliable in the setting of severe illness. No currently available kit actually measures 
unbound T4 directly. Free thyroid hormone levels can be estimated by calculating the 
percentage of available thyroid hormone-binding sites (T3 resin uptake) or by 
measuring the concentration of TBG. A free thyroxine index (FTI) serves as a 
surrogate of the free hormone level. The FTI is the product of the T3 resin uptake and 
total T4 levels. Patients with primary hypothyroidism have elevated TSH levels and 
decreased free hormone levels. Patients with elevated TSH levels but normal free 
hormone levels or estimates are considered to have mild or subclinical 
hypothyroidism increased conversion of T4 to T3 occur this maintains T3 levels In 
early hypothyroidism. Evaluation of the presence of thyroid autoantibodies 
(antimicrosomal or anti-TPO antibodies) and antithyroglobulin (anti-Tg) may be 
helpful in determining the etiology of hypothyroidism or in predicting future 
hypothyroidism. In addition, anti-TPO antibodies have been associated with a higher 
risk of infertility and miscarriage. In patients with hypothalamic or pituitary 
dysfunction, TSH levels do not increase in appropriate relation to the low free T4 
levels. The absolute levels may be in the normal or even slightly elevated range but 
inappropriately low for the severity of the hypothyroid state. Hence, when secondary 
or tertiary hypothyroidism is suspected, a serum TSH measurement alone is 
inadequate; a free T4 should be measured. The TRH stimulation test is rarely needed 
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currently because of improved TSH assays when performed; there will be no TSH 
response to exogenous TRH in cases of destructive lesions of the pituitary. In patients 
with hypothalamic disease, the peak TSH response to TRH may be normal, but is 
generally delayed until 45 or 60 minutes after the TRH administration rather than 
after usual time of 20 to 30 minutes.  
1.2.1.4.2.1. Histological findings 
Autoimmune thyroiditis causes a decrease in intrathyroidal iodine stores, an increased 
iodine turnover, and defective organification. Chronic inflammation of the gland 
causes progressive destruction of the functional tissue with widespread infiltration by 
lymphocytes and plasma cells with epithelial cell abnormalities. In time, dense 
fibrosis and atrophic thyroid follicles replace the initial lymphocytic hyperplasia and 
vacuoles. Functional tissue destruction and infiltration may also be caused by 
previous administration of radioiodine, surgical fibrosis, metastasis, lymphomatous 
changes, sarcoidosis, tuberculosis, amyloidosis, cystinosis, thalassemia, and Riedel 
thyroiditis. 
1.2.1.4.3. Treatment 
The treatment goals for hypothyroidism are the reversal of clinical progression and 
the corrections of metabolic derangements, hypothyroidism can be adequately treated 
with a constant daily dose of levothyroxine (LT4). Clinical benefits begin in 3-five 
days and level off after 4-6 weeks. In elderly patients or those with known ischemic 
heart disease, treatment should begin with one fourth to one half the expected doses. 
Achieving a TSH level within the reference range may be slowed because of delay of 
hypothalamic-pituitary axis readaptation and may take several months. After dose 
stabilization, patients can be monitored with annual clinical evaluations and TSH 
monitoring. Patients should be monitored for symptoms and signs of overtreatment, 
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which include tachycardia, palpitations, nervousness, tiredness, headache, increased 
excitability, sleeplessness, tremors, and possible angina (9). 
 
1.2.1.4.1.3. Subclinical hypothyroidism 
Significant controversy persists regarding the treatment of patients with mild 
hypothyroidism. Some have argued that treatment of these patients improves 
symptoms, prevents progression to overt hypothyroidism, and may have 
cardioprotective benefits. The American Association of Clinical Endocrinologists 
(AACE) guidelines state that treatment is indicated in patients with TSH levels above 
ten mIU/mL or in patients with TSH levels between 5 and 10 mIU/mL in conjunction 
with goiter and/or positive antithyroid peroxidase antibodies, as these patients have 
the highest rates of progression to overt hypothyroidism. An initial dose of 25-50 
mcg/d of LT4 can be used and can be titrated every 6-8 weeks, to achieve a target 
TSH of between 0.3 and 3 mIU/mL (9). 
1.2.1.4.1.4. Myxedema coma 
An effective approach is to use intravenous LT4 at a dose of 4 mcg/kg of lean body 
weight, or approximately 200-250 mcg as a bolus in a single or divided dose, 
depending on the patient's risk of cardiac disease followed by 100 mcg 24 hours later 
and then 50 mcg daily IV or PO along with stress doses of intravenous 
glucocorticoids. Use of intravenous triiodothyronine is controversial and based on 
expert opinion. It has a higher frequency of adverse cardiac events and is generally 
reserved for patients who are not improving clinically on LT4. LT3 can be given 
initially as a 10 mcg IV bolus and repeated every 8-12 hours until the patient can take 
maintenance oral doses of T4. Advanced age, high dose T4 therapy, and cardiac 
complications had the highest associations with mortality.  Suspected myxedema 
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coma is a medical emergency with a high risk of mortality that requires initiation of 
parenteral (intravenous) LT4 and glucocorticoids prior to laboratory confirmation. 
Follow up: once appropriate theraputic dose is mantained, patients can be monitered 
annualy or semi-annualy with lab tests ((TSH,T4,T3),TpoAbs) and physical 
examination (9). 
1.2.1.4.2. Hyperthyroidism 
1.2.1.4.2.1. Thyrotoxicosis  
 Is the hypermetabolic condition associated with elevated levels of free thyroxine 
(FT4) and/or free triiodothyronine (FT3). Hyperthyroidism includes diseases that are a 
subset of thyrotoxicosis, that are caused by excess synthesis and secretion of thyroid 
hormone by the thyroid; they are not associated with exogenous thyroid hormone 
intake and subacute thyroiditis the most common forms of hyperthyroidism include 
diffuse toxic goiter (Graves disease), toxic multinodular goiter (Plummer disease), 
and toxic adenoma. Together with the thyrotoxic phase of  subacute thyroiditis, these 
conditions constitute 85-90% of all causes of thyrotoxicosis. Less common causes are 
iodine induced thyrotoxicosis and thyrotoxicosis factitia. Uncommon causes are TSH 
secreting pituitary tumor,excess HCG (molar pregnancy, choriocarcinoma), thyroid 
hormone resistance, metastatic thyroid cancer, struma ovarii with thyrotoxicosis (9). 
1.2.1.4.2.1.1. Symptoms and signs 
Nonspecific changes due to excessive thyroid hormone include weight loss, 
nervousness, fatigue, heat intolerance, and rapid heartbeat or palpitations sometimes 
associated with atrial fibrillation and high-output congestive heart failure (CHF) and 
increase in the rate of bone resorption. Thyroid hormone excess causes left ventricular 
thickening, which is associated with an increased risk of CHF. Thyrotoxicosis has 
been associated with dilated cardiomyopathy, right heart failure with pulmonary 
18 
hypertension. Ophthalmopathy and dermopathy specifically associated with Graves 
disease include periorbital edema, chemosis, and proptosis with extraocular muscle 
dysfunction and diplopia. The dermopathy, a painless swelling of the pretibial area 
may occur in patients with severe opthalmopathy (9). 
1.2.1.4.2.2. Grave's disease 
The most common cause of thyrotoxicosis is Graves disease (50-60%). Graves 
disease is an organ-specific autoimmune disorder characterized by a variety of 
circulating antibodies, including common autoimmune antibodies, as well as anti-
thyroid peroxidase (anti-TPO) and antithyroglobulin (anti-TG) antibodies. The most 
important autoantibody is thyroid-stimulating immunoglobulin (TSI). TSI is directed 
toward epitopes of the thyroid-stimulating hormone (TSH) receptor and acts as a 
TSH-receptor agonist. Similar to TSH, TSI binds to the TSH receptor on the thyroid 
follicular cells to activate thyroid hormone synthesis and release and thyroid growth 
(hypertrophy). This results in the characteristic picture of Graves thyrotoxicosis, with 
a diffusely enlarged thyroid, very high radioactive iodine uptake, and excessive 
thyroid hormone levels compared with a healthy thyroid. The disease has got a peak 
occurrence in people aged 20 to 40 years, and a male: female ratio of 1.5 – 10. 
Usually there is a strong family history past medical history of other autoimmune 
diseases like rheumatoid arthritis, vitiligo and pernicious anaemia. The disease has 
higher prevalence in patients with HLA-DRw3 and HLA-B89. (11). 
1.2.1.4.2.2.1. Laboratory Studies 
TSH levels usually are suppressed to immeasurable levels (<0.05 µIU/mL) in 
thyrotoxicosis. Third-generation TSH assays are recommended for screening 
purposes. The degree of thyrotoxicosis cannot be estimated easily by the TSH level 
and must be measured using an assay of thyroid hormone levels in the plasma. 
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Therefore, measuring free T4 (and T3 if T4 levels are normal) is recommended in 
patients with suspected thyrotoxicosis when TSH is low.(11) 
Subclinical hyperthyroidism is defined as a suppressed TSH level (<0.5 µU/mL in 
many laboratories) in combination with serum concentrations of T3 and T4  that are 
within the reference range (11). 
Thyroid autoantibodies:  
The most specific autoantibody for autoimmune thyroiditis is an enzyme-linked 
immunosorbent assay (ELISA) for anti-TPO antibody. The titers usually are 
significantly elevated in the most common type of hyperthyroidism, Graves 
thyrotoxicosis, and usually are low or absent in toxic multinodular goiter and toxic 
adenoma. A significant number of healthy people without active thyroid disease have 
mildly positive TPO antibodies; thus, the test should not be performed for screening 
purposes. TSI, if elevated, helps establish the diagnosis of Graves disease. A positive 
anti-TG antibody test does not predict the development of thyroid dysfunction and 
should not be measured (11). 
Radioisotope scanning: helps differentiate different types of hyperthyroidism (11). 
1.2.1.4.2.3. Euthyroid Goiter 
Defenition: diffuse or nodular, is noncancerous hypertrophy of the thyroid without 
hyperthyroidism, hypothyroidism, or inflammation. The most common type of thyroid 
enlargement during puberty, pregnancy, and menopause. 
1.2.1.4.2.3.1. Etiology 
a) Intrinsic thyroid hormone production defects: 
• Iodine deficiency (endemic goiter) 
• Goitrogens. 
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b) Regular use of medications that decrease thyroid hormone production e.g.anti 
thyroid drugs & iodine containing compounds. 
c) Familial (12). 
1.2.1.4.2.4. Thyroid cancer 
Is the cancerous enlargement of the thyroid gland. 
Risk factors include: previous irradiation of the neck, positive family history and 
chronic goiter. 
Histological types include: papillary, medullary, follicular and anaplastic. 
Clinical presentation include: neck swelling, difficulty in swallowing, hoarseness of 
the voice and thyroid lump. 
1.2.1.4.2.4.1. Tests for thyroid cancer 
I. Elevated serum calcitonin (for medullary cancer) or serum thyroglobulin (for 
papillary or follicular cancer) 
II. Laryngoscopy showing paralyzed vocal cords 
III. Thyroid biopsy showing anaplastic, follicular, medullary, or papillary cancer cells 
IV. Thyroid scan showing a nodule that does not light up on the scan (cold nodule) 
1.2.1.4.2.4.2. Treatment: surgery, radiotherapy (13).  
1.2.1.4.2.5. Euthyroid sick syndrome (low T3 syndrome)  
Can be described as abnormal findings on thyroid function tests that occur in the 
setting of a no thyroidal illness (NTI), without preexisting hypothalamic-pituitary and 
thyroid gland dysfunction (14). 
TSH secretion is normal or decreased, total T4 levels are decreased, and total T3 
levels are markedly decreased. This can be confused with secondary hypothyroidism. 
In these patients, the primary abnormality is the decreased peripheral production of 
T3 from T4. They have an increased reverse T3, which can be measured (14). 
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1.2.2. Selenium and the thyroid 
1.2.2.1. Selenium and selenoproteins 
The essential trace element, selenium (atomic number 34, atomic mass 78.96, a non 
metal chemically related to sulfur and tellurium), and which we largely obtain from 
bread and cereals, fish, poultry and meat, plays a vital part in many metabolic 
functions. While new research increasingly suggests its relevance to disease 
prevention, evidence that dietary intake is falling in some parts of the world is giving 
cause for concern (15) 
The amount of selenium available in the soil varies and this affects the amount of 
selenium found in local produce. High levels of selenium are found in the high plains 
of northern Nebraska and the Dakotas whereas the soil in some parts of China and 
Russia has scant amounts of selenium. In areas where the diet primarily consists of 
locally grown food, selenium levels in the body correlate well to soil levels.(16)  
The daily value recommended for selenium by the FDA is 70 mcg. When 
supplements are used, 100-200 mcg daily of selenomethionine is recommended. 
Amounts greater than 200 mcg should be avoided. Results of the National Health and 
Nutrition Examination Survey indicate that most Americans obtain adequate selenium 
from diet. However, studies also show a lower rate of cancer, heart disease and 
autoimmune thyroid disease in patients with higher selenium levels. Surveys also 
show that patients with rheumatoid arthritis with lower selenium levels have more 
swelling, pain, stiffness and loss of function in their joints(16). 
1.2.2.2. Selenium Deficiency 
Selenium deficiency is thought to contribute to autoimmune disease by making the 
body more susceptible to nutritional and biochemical stresses as well as infectious 
diseases. Three diseases caused directly by selenium deficiency include Keshan 
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Disease, which causes an enlarged heart, Kashin-Beck Disease, which causes 
osteoarthropathy, and Myxedematous Endemic Cretinism, a form of hypothyroidism 
which results in mental retardation (17). 
1.2.2.3. Selenium toxicity 
 Occurs when doses higher than 400 mcg daily are ingested over time, causes a 
condition of selenosis. Symptoms include garlic breath odor, hair loss, white blotchy 
nails, irritability, fatigue, gastrointestinal upset and mild nerve damage. Selenium 
toxicity is rare in the United States and primarily is related to industrial accidents (17). 
Selenium was discovered by the Swedish chemist Berzelius in 1817, but a biological 
role for this trace element remained unknown until 1957 when Schwarz and Foltz 
showed that selenium deficiency could cause necrotic liver degeneration. However, 
the first real understanding of the physiological basis for a selenium nutritional 
requirement did not occur until 1973, when it was shown that selenium was an 
essential component of mammalian enzymes like glutathione peroxidases (GPx). It is 
now well established that selenium plays an important biological role in living 
organisms, mostly through its incorporation in a family of proteins called 
selenoproteins. The main biological form of selenium is selenocysteine (Sec), a 
cysteine analog that is synthesized from a serine bound to tRNA. Sec is identical to 
cysteine except for the fact that, in place of sulfur, it contains a selenium atom, which 
is typically ionized at physiological pH. In several instances, replacement of Sec by 
cysteine in a selenoprotein has been shown to result in a dramatic decrease of 
enzymatic activity, supporting the concept that the ionized selenium atom is critical 
for proper protein function (18). 
The single unifying, and defining, feature of selenoproteins is the fact that they all 
include one or more Sec residues in their primary structure. To date, all selenoproteins 
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with known functions, with the exception of selenoprotein P appear to have enzymatic 
activities in which the Sec residue is located at the catalytic site, where it likely 
participates in redox reactions. However, the amino acid sequences, enzymatic 
activities, tissue distribution of expression, and other molecular features of the 
different family members are extremely varied. Similarly, at the physiological level, 
these enzymes are involved in diverse metabolic and physiological functions ranging 
from antioxidant defense to fertility, muscle development and function, thyroid 
hormone metabolism, and immune function. Consequently, the range of pathologies 
associated with primary or secondary defects of selenoprotein function is enormous, 
with no easily definable unifying feature to tie together this disparate group of 
phenotypes at the pathophysiological level. 
1.2.2.4. Selenoprotein Biosynthesis 
The incorporation of Sec, which is considered to be the 21st amino acid, occurs in a 
unique and peculiar way; in fact, the Sec codon is an in-frame UGA, which normally 
corresponds to a termination codon. The recognition of UGA as a Sec codon, instead 
of a translational stop signal, requires the presence of a stem loop sequence called 
SECIS (SEC insertion sequence), which typically resides several hundred to several 
thousand base pairs downstream of the UGA codon in the 3' untranslated regions of 
eukaryotic selenoprotein transcripts. Interestingly, the targeted deletion of tRNASec 
gene (Trsp) results in an embryonic lethal phenotype in mice. Now 25 human 
selenoprotiens were identified (18). 
1.2.2.5. Glutathione peroxidase (GPx) and Disease  
Selenium containing enzyme that protects tissues from oxidative damage by removing 
peroxides resulting from free radical action, linked to oxidation of glutathione; part of 
the body’s antioxidant protection (18). 
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Decreased antioxidant activity occurs in selenium deficiency and renders patients 
susceptible to viral infections, cancers and autoimmunity. An example is the dilated 
cardiomyopathy in Keshan disease patients is likely related to decreased activity of 
GPx-1, secondary to selenium deficiency, which allows the accumulation of 
coxsakievirus mutations, hence converting benign strains into cardio toxic ones (18). 
To date, all selenoproteins with known functions have enzymatic activity. However, it 
is noteworthy that GPx-4, in addition to its enzymatic function, can also play a 
structural role in mature spermatozoa, impairment of GPx-4 is highly suspected to 
result in male infertility (18).  
1.2.2.6. TrxRs and Disease 
As their name implies, TrxRs reduce thioredoxins (Trxs), which are small, ubiquitous, 
redox-active peptides with a conserved catalytic site that undergoes reversible 
oxidation/reduction at two Cys residues, TrxRs are involved in a broad range of 
physiological and pathological pathways ranging from cancer to sperm maturation 
and male fertility (18). 
1.2.2.7. Selenoprotein P and Selenium Transport 
Selenoprotein P (SEPP1) is unique among selenoproteins because, in humans, it 
incorporates 10 Sec residues. It is a secreted protein that contains about 50% of the 
selenium content of human plasma, and it appears to be important for transporting 
selenium to the brain. Other selenoprotiens are selenoprotien s involved in 
inflammation, selenoprotien 15kda related to cancer and tumor progression, 
selenoprotien n related to muscle diseases. An important selenoprotiens involved in 
thyroid hormone metabolism are the iodothyronine deiodinases (18). 
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1.2.3. Selenium, selenoprotiens and thyroid disease 
The thyroid gland has an exceptionally high selenium content, even during selenium 
deficiency. At least 11 selenoproteins are expressed, which may be involved in the 
protection of the gland against the high amounts of H2O2 produced during thyroid 
hormone biosynthesis. As determined here by in situ hybridization and Northern 
blotting experiments, glutathione peroxidases (GPx) 1 and 4 and selenoprotein P were 
moderately expressed, occurring selectively in the follicular cells and in leukocytes of 
germinal follicles of thyroids affected by Hashimoto's thyroiditis. Selenoprotein 15 
was only marginally expressed and distributed over all cell types. GPx3 mRNA was 
exclusively localized to the thyrocytes, showed the highest expression levels and was 
down-regulated in 5 of 6 thyroid cancer samples as compared to matched normal 
controls (19). 
Selenium dficiency (reducing selenoprotiens activity), and disturbed thyroid function 
may develop under conditions of special dietary regimens, such as long term total 
parentral nutrition TPN , or after inadequate nutrition in children (20). 
1.2.3.1. The role of selenium in thyroid autoimmunity and cancer 
The selenoenzyme families of glutathione peroxidases (GPx) and thioredoxin 
reductases (TRx) possess powerful antioxidant properties and form a complex defense 
system that protects thyrocytes from oxidative damage. Se supplementation in 
patients with autoimmune thyroiditis seems to modify the immune response, probably 
by enhancing plasma GPx activity and decreasing excess levels of hydrogen peroxide. 
However, the enhancement of immunocompetence may also be the result of the 
synergistic action of various selenoproteins and not exclusively of GPx. There is 
evidence supporting considerable oxidative stress in Graves' disease where Se 
supplementation, because of its free radical scavenging properties, may increase the 
26 
enzymatic antioxidant activity. TRx has been found significantly elevated in GD 
revealing its involvement in the pathogenesis of this condition and representing a 
potential future target for therapeutical intervention (21). 
Selenium deficiency has been implicated in the etiology of Hashimoto's thyroiditis, 
and just by supplementing with selenium, there will usually be a decrease in antibody 
levels. This was shown in an elegant study from Crete published in 2007. This study 
reported a 21 % reduction in TPO antibodies after one year of selenomethionine 
supplements(200 mcg per day) (22). 
Low Se serum levels have also been associated with increased risk of thyroid cancer 
and may play a role in carcinogenesis. It is noteworthy, that the Food and Drug 
Administration has recently determined that there is sufficient evidence to warrant a 
qualified health claim for Se and cancer. Furthermore, the recent discovery that 
defects in the SECIS-binding protein 2 (SBP2), which is an indispensable protein for 
the incorporation of Se into the selenoproteins, result in thyroid dysfunction, together 
with the recognition of the many roles of selenoprotein P in Se distribution and 
storage in the human body, reveal not only the indispensability of Se and the 
selenoproteins as essential factors in thyroid metabolism and pathogenesis, but open 
up new prospects for enhanced treatment (21). 
1.2.3.2. Selenium & peripheral thyroid hormone metabolism  
The iodothyronine deiodinases types I, II, and III (D1, D2, and D3, respectively) 
regulate the activity of thyroid hormone via removal of specific iodine moieties from 
the precursor molecule T4. These 3 enzymes constitute a group of dimeric integral 
membrane thioredoxin fold–containing proteins that can activate or inactivate thyroid 
hormone, depending on whether they act on the phenolic or tyrosil rings of the 
iodothyronines, respectively. D2 generates the active form of thyroid hormone T3 via 
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deiodination of T4. In contrast, D3 inactivates T3 and, to a lesser extent, prevents T4 
from being activated. Finally, D1 is a kinetically inefficient enzyme that activates or 
inactivates T4 on an equimolar basis, and its role in health remains to be clarified. In 
general, a given cell type will express only 1 type of deiodinase at a given time, 
though some tissues express none, and some express all the 3.for example D1 is 
expressed mainly in the liver, kidney and muscle.D2 is expressed mainly in the 
pituitary and brain. Thyroid hormone signaling results from the interaction of nuclear 
thyroid hormone receptors (TRs) with specific target gene promoters, a process that 
can either enhance or repress transcription (23). 
This process is modulated via binding of thyroid hormone, the ligand, to the TRs, 
which results in alterations in the composition of the transcriptional complex. 
Signaling through this pathway is, of course, sensitive to changes in serum thyroid 
hormone concentrations,  the modern paradigm of thyroid hormone action also 
recognizes that thyroid hormone signaling in individual tissues can change even as 
serum hormone concentrations remain normal, thanks to local activation or 
inactivation of thyroid hormone. The underlying mechanism of these phenomena is 
deiodination. The deiodinases are critical determinants of the cytoplasmic T3 pool 
(80% of T3 is formed from peripheral deiodination of T4) and therefore modulate 
nuclear T3 concentration and TR saturation (23). 
In the pituitary thyrotroph, TSH is subject to negative feedback by T3, which is 
largely obtained by deiodination by pituitary D2. The actions of the deiodinases are 
integrated and thus promote the maintenance of serum T3 concentrations. 
Fluctuations in serum T4 and T3 concentrations lead to homeostatic, reciprocal 
changes in the activity of D2 and D3. As serum T3 concentrations increase, 
expression of type III iodothyronine deiodinase (Dio3), which encodes D3, is 
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upregulated, increasing T3 clearance, while expression of Dio2, which encodes D2, is 
modestly downregulated, decreasing T3 production. Conversely, if serum T3 
concentrations were to fall, downregulation of the D3 pathway would decrease the 
clearance of T3 (23). 
The increase in plasma T4 and decreases in T3 in the selenium deficient rats (given 
selenium deficient diets compared to rats given selenium adequate diets) indicated 
that the conversion of T4 to T3 by the D1 in the liver and kidney was diminished 
possibly as a consequence of the enzyme being a selenoprotein. The decrease in D2 in 
selenium deficiency  also suggested that D2 may also be a selenoenzyme;however, 
D2  activity may also be modified by plasma T4 concentration, with high T4 
inhibiting D2 activity (24).  
Under normal circumstances an increase in plasma free T4 decreases plasma TSH, but 
in the hyperthyroxinaemia of selenium deficiency, plasma TSH is unchanged or 
increased, indicating an inability of the pituitary to recognize the high free T4due to 
the impaired intrapituitary conversion of T4 to T3. 
Selenium deficiency either through a direct effect or through elevated plasma TSH 
causes an increase in thyroidal T3 and T4 synthesis at the expense of a decrease in the 
total thyroidal iodine even when there is an adequate supply of iodine in the diet (24). 
The effects of combined selenium and iodine deficiencies have been evaluated in 
different fluids and tissues, such as plasma (25), central nervous system (26), brown 
adipose tissue, liver and thyroid (27) reported that combined selenium and iodine 
deficiencies significantly lowered thyroidalT3 and plasma T4 compared with rats with 
single iodine deficiency, also plasma TSH concentration and thyroid weight are 
significantly greater (28). 
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In African countries like Zaire, there are areas where both iodine and selenium are 
very scarce in the soil (these deficiencies seem to run parallel in most areas). 
Consequently a high percentage of the people have goiters and hypothyroidism (24). 
Studies have shown that if iodine is low, selenium must also be kept low to prevent 
the hypothyroidism from becoming worse (from increased D-I and T4 depletion, as 
explained above.) So if both minerals are low, then the person is hypo and gets a 
goiter, but the damage to the thyroid is kept to a minimum. More severe problems 
happen when either selenium or iodine is high and the other is low. If selenium is high 
and iodine low, then T4 to T3 to T2 conversion is accelerated without T4 being 
replenished, leading to a worsening of the hypothyroidism. If iodine is high and 
selenium is low, then H2O2 is not degraded by GPX. Since H2O2 drives the thyroid 
hormone production, then the thyroid over-produces thyroid hormone (Grave's 
hyperthyroidism), the thyroid is damaged from the oxidation by the H2O2, and the 
end result is that the damaged thyroid ultimately decreases activity and 
hypothyroidism results (Hashimoto's thyroiditis). This could explain the observed 
progression of Grave's to Hashimoto’s (29) 
Selenium deficiency is common in the critically ill patients and this could play a role 
in the pathogenesis of the low T3 syndrome .The syndrome also occurs after major 
surgery and life threatening traumas (e.g. head injuries).  After severe injury, T4 
deiodination is decreased, leading to the low T3 syndrome. Injury increases free 
radical production, selenium is redistributed in the tissues, and the iodothyronine 
deiodiodinases are inactivated (30). 
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1.3. JUSTIFICATION  
1- Selenium is one of the essential trace elements that guard our bodies against 
autoimmunity and cancer. 
2-It is decided to study selenium status in thyroid diseases (hypo and 
hyperthyroidism), since thyroid disorders are very common in our country. 
3- Many studies documented that the soil in Sudan, especially in Darfur is deficient in 
both selenium and iodine rendering Sudanese people more susceptible to goiter and 
thyroid diseases. 
4-It is also documented from many studies that supplementing these patients with 
selenium helps to improve the disease outcome, thereby reducing morbidity and 
mortality, and this is especially for autoimmune thyroid diseases where selenium 
plays a major role in reducing auto antibodies levels. 
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1.4. OBJECTIVES 
1.4.1. General objectives: 
To evaluate serum selenium level in thyroid disease (hypo and hyper thyroid 
patients). 
 
1.4.2. Specific objectives: 
1- To measure serum selenium level in hypothyroid, hyperthyroid patients and normal 
controls (age and sex matched groups). 
2- To compare serum  selenium level in hypo and hyperthyroid patients’ pre and post 
treatment of their thyroid disease. 
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2. MATERIALS AND METHODS 
2.1. Study design: 
Prospective hospital based case control study. 
2.2. Study area: 
The study was conducted in Khartoum teaching hospital. It was chosen since it is a 
central large federal hospital and most of the patients are seen there. The study was 
conducted in the clinical chemistry department of Khartoum teaching hospital 
laboratories. 
2.3. Study duration: 
The study was conducted during the period (September 2010 to February 2011). 
2.4. Study population: 
2.4.1. Cases: 
Inclusion criteria: male and female adults (age 16 years and above )who were 
diagnosed as having hypothyroidism (group 1) and hyperthyroidism (group 2) on the 
basis of clinical presentation and laboratory investigations (performing thyroid 
function tests) and who were voluntarily accepting to participate in the study. 
Exclusion criteria: subjects known to have low selenium like asthmatics and cancer 
patients. 
2.4.2. Controls: male and female adults who were found to be euthyroid both 
clinically and biochemically (performing thyroid function tests), and have no 
evidence of thyroid disease ( e.g. goiter). 
2.5. Sampling technique: 
2.5.1. Ethical consideration: 
Ethical approval was given by the director of Khartoum Teaching Hospital laboratory.  
Consents were obtained from the study subjects before entry into the study. 
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2.5.2. Sample size: 
Forty cases (20 hypothyroid and 20 hyperthyroid) Twenty  age and sex matched 
normal controls. 
2.6. Data collection: 
Data were collected from patients by questionnaire (appendix 1). The questionnaire 
included demographic characteristics, disease identification data, treatment details, 
and results of thyroid function tests and serum selenium levels were also included. 
2.7. Collection of blood samples: 
Five ml of venous blood withdrawn in a plain container, centrifuged for 15 minutes, 
two ml of clear serum were obtained and divided equally for thyroid function tests 
(TSH, total T4& total T3) and for selenium measurements.  
2.8. Technique of biochemical analysis: 
Thyroid function tests were measured by using the principle of chemiluminescence by 
Elecsys 2010 (Roche). 
Serum selenium was measured in diluted samples (5times dilutions with distilled 
water & nitric acid) by using the principle of atomic absorption by AA 6800 atomic 
absorption spectrophotometer (Shimadzu) (appendix 2). 
2.9. Quality control: serial dilutions of a commercially prepared selenium standard 
(thousand ppb concentration) were used to prepare the standard (absorbance vs. 
concentration) calibration curve. Sample concentration was obtained from the curve. 
Each sample was read three times and the mean of the closest two readings was 
derived.    
2.10. Data analysis: 
Data were analyzed by computer system using SPSS program. 
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2.11. Data interpretation: 
Thyroid hormones and TSH were determined as high, low or normal according to the 
laboratory reference ranges. 
Serum selenium was also determined as low, high or normal (adult reference range 
between 75 and 120 ppb). 
Final results were presented in tables and figures. 
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3. RESULTS 
 
3.1. Demographic characteristics of the study group 
3.1.1. Gender distribution: 
The studied subjects were 60 (40 cases and 20 controls).Fifty six of them were 
females (93.3%), with only 4 males included (6.7%). (Figure 1). 
3.1.2. Age distribution: 
Most of the studied subjects were in the age group from 31 to 50 years (53.3%).   
With (41.7%) in the age group from 16 to 30 years and only 5% age >50 
years.(Figure 2). 
3.2. Disease identification: 
Of the hypothyroid group 14 patients (70%) were on treatment with thyroxine .Six 
patients (30%) were not on treatment, of which three (15%) were not started on 
treatment (new cases) and the remaining 3 patients were on treatment but stopped. 
Regarding the hyperthyroid group 12 patients (60%) were on treatment, 7patients 
were on treatment and stopped (35%). Only 1 patient (5%) was not started on 
treatment (new case). 
3.3. Serum selenium level in the studied subjects: 
 3.3.1. Serum selenium level in the controls: 
The mean serum selenium level in the normal controls was 78.39 ppb (+ 17.99SD). 
(Figure 3). 
3.3.2. Serum selenium level in the hypothyroid group: 
The mean serum selenium level in the hypothyroid group of patients was 63.82 ppb                              
(+ 26.2SD). (Figure 4). 
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The mean serum selenium of the hypothyroid group was significantly low compared 
to controls (P value<0.05). (Table 1). 
3.3.3. Serum selenium level in the hyperthyroid group: 
The mean serum selenium level in the hyperthyroid group of patients was 81.89ppb                       
(+ 29.9SD). (Figure 5).The mean serum selenium was statistically insignificant 
compared to controls. (Table 2). 
3.4. Serum selenium level in the studied cases pre & post treatment: 
3.4.1. Serum selenium level in the hypothyroid group pre & post treatment with 
thyroxine: 
The mean serum selenium level in the hypothyroid group who were not started on 
treatment (new cases) was 30.54ppb (+ 24.68SD).  
The mean serum selenium level in the hypothyroid patients who are on replacement 
with thyroxine was 74.71ppb (+ 17.57SD).  
The difference was statistically significant (P value<0.05). (Table3). 
The mean serum selenium level in the hypothyroid patients who were on treatment 
but now stopped was 52.8ppb (+ 27.1SD).  
3.4.2. Serum selenium level in the hyperthyroid group pre & post treatment with 
anti thyroid drugs: 
The mean serum selenium level in the hyperthyroid patients who are on treatment 
with ant thyroid drugs was 87.96ppb (+ 35.05SD).  
The mean serum selenium level in the hyperthyroid patients who were on treatment 
but now stopped was 73.07ppb (+ 20.16SD).  
Only one patient was never been on treatment (new case) with a level of 70.8ppb. 
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3.5. Effect of serum selenium level on TSH & thyroid hormones in thyroid 
disease: 
3.5.1. Effect of serum selenium level on TSH: 
In the hypothyroid group of patients the mean serum selenium level was 63.82ppb 
(reference range from 75 to 120 ppb) and the mean TSH was 20.06 (reference range 
from 0.5 to 5µU/ml).The relation is statistically significant (P value<0.05). 
In the hyperthyroid group the mean selenium was 81.89ppb and the mean TSH 
 Was 2.36 µU/ml the relation is statistically significant (P value <0.05). (Table 4). 
3.5.2. Effect of serum selenium level on T4: 
In the hypothyroid group mean selenium was 63.82ppb. The mean T4 was 5.9µg/dl 
(reference range from 4.5 to 13µg/dl).The relation is statistically significant  
 (P value<0.05). 
In the hyperthyroid group of patients mean selenium was 81.89 and the mean T4 was 
11.08.The relation is not statistically significant. (Table 5). 
3.5.3. Effect of serum selenium level on T3: 
In the hypothyroid group mean selenium was 63.8ppb and the mean T3 was 1.4µg/dl. 
In the hyperthyroid group mean selenium was 81.89 ppb and the mean T3 
 was 3.7µg/dl. Both relations were statistically insignificant. 
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Figure 3: Serum selenium level in the euthyroid group 
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Figure 4 Serum selenium levels in hypothyroid patients 
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Figure 5 Serum selenium levels in hyperthyroid patients 
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 Table 1: Correlation between mean serum selenium levels in the 
hypothyroid group and controls. 
                                                P value<0.05 
 
 
Minimum 
Selenium 
value 
Maximum 
Selenium 
value 
Mean 
Selenium 
value 
Std. 
Deviation 
Hypothyroid 10.9 101.4 63.82 26.29 
Euthyroid 32.6 99.3 78.39 17.99 
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Table 2: Correlations between mean serum selenium levels in the 
hyperthyroid group and controls 
 
 
Minimum 
Selenium 
level 
Maximum  
Selenium 
level 
Mean 
Selenium 
level 
Std. 
Deviation 
Hyperthyroid 45 160 81.89 29.93 
Euthyroid 32.6 99.3 78.39 17.99 
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Table 3: Correlations between mean serum selenium levels in the 
hypothyroid patients’ pre and post treatment with thyroxine 
P value <0.05 
 
Number of 
cases 
Mean 
Selenium level 
Std. 
Deviation 
New cases 
(not started on treatment) 
3 30.54 24.6 
Patients on thyroxine 14 74.71 17.57 
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Table 4: Correlations between mean selenium level and TSH in thyroid 
disease 
                                                        P value<0.05 
 
Mean  
Selenium level 
Mean  
TSH (0.5 - 5µU/ml) 
Hypothyroid 63.82 20.06 
Hyperthyroid 81.89 17.9 
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Table5:  Relations between thyroid hormones T3 and T4 and serum 
selenium in thyroid disease  
 
Mean 
Serum 
selenium 
Mean 
Serum T4 
Ref. 4.5 -
13µg/dl 
P 
value 
Mean 
Serum T3 
Ref. 0.8 -
2µg/dl 
P 
value 
Hypothyroid 63.82 5.9 <0.05 1.4 >0.05 
Hyper thyroid 81.89 11.08 >0.05 3.7 >0.05 
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4.1. DISCUSSION 
The thyroid gland has exceptionally high selenium content. Selenoprotiens are 
involved in the protection of the gland against the high amounts of hydrogen peroxide 
produced during thyroid hormone biosynthesis. Selenium deficiency has been 
implicated in the etiology of many thyroid diseases, namely hypothyroidism, 
autoimmune thyroid disease (ATD), and endemic cretinism. 
This study is a hospital based, case control, in which serum selenium levels were 
measured in hypo and hyperthyroid patients and compared to levels of healthy age 
and sex matched controls. 
Selenium levels were determined as low, normal or high according to the international 
reference range from 75 to 120 ppb {equivalent to µg/dl}, levels below 75 ppb were 
considered low, and those above 120 ppb were considered high. 
In this study, it was found that the mean serum selenium level in the hypothyroid 
group of patients was significantly low compared to controls. The level was even 
lower significantly in the newly diagnosed cases, though they were only three in 
number. Interestingly, among those newly diagnosed one case presented with 
myxedema (generalized swelling, hoarseness, sleepiness and hypotension) and had 
got the lowest serum selenium level. The mean serum selenium level in the 
hypothyroid patients receiving l-thyroxine replacement was found to be significantly 
higher than the level in the new cases (not started on treatment), although both levels 
were still below the lower limit of the reference range. 
Mean serum selenium level was intermediate in the hypothyroid patients who were on 
thyroxine replacement but stopped. The reasons for stopping treatment in most cases 
were pregnancy and lactation. Unfortunately, bad follow up was the cause in many 
others. 
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Similar findings were obtained by a group of researchers who had reported 
significantly low selenium levels in hypothyroid patients compared to controls (31). 
Another study from Crete published in 2007, reported low selenium level in patients 
with Hashimoto,s thyroiditis (considered to be the commonest cause of 
hypothyroidism) and they also reported a 21% reduction in the TPO antibodies after 
one year of selenomethionine supplements (22). 
In contrast, other group of researchers who studied serum selenium level in hypo and 
hyperthyroid patients (in three areas with different iodine intake ) compared to normal 
controls found no difference in serum selenium levels between patients with 
subclinical hypothyroidism, clinical hypothyroidism and clinical hyperthyroidism and 
their normal controls (32) 
Regarding the effect of treatment on the improved selenium levels, no solid data was 
found in the literature whether l-thyroxine helps correct selenium deficiency in 
hypothyroidism or not. But, it was found in the literature that hypothyroidism as a 
result of break down in the conversion of T4 to T3 ( as could be in selenium 
deficiency ) will benefit little from l-thyroxine as it is a prohormone and needs to be 
converted to the active form (T3) (29). 
Putting in mind that the studied cases were not on selenium supplements or selenium 
rich diet so, this desired treatment effect needs to be further explored. 
In the hyperthyroid group of patients, the mean serum selenium level was within the 
reference range and found to be higher than the level of the controls but this finding 
was statistically insignificant. 
In the literature low selenium (but with adequate or high iodine) can lead to the 
development of Grave’s hyperthyroidism (24). 
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Studying the relationships between serum selenium and thyroid hormones (total T4 
and T3) and TSH, it was concluded that serum selenium was inversely correlated with 
TSH and T4. No significant relationship was found between serum selenium and T3. 
The insignificant P value may be justified by the small size of the sample population. 
In the literature one study showed that serum selenium correlates directly with T3 and 
inversely with TSH (33). Another group of researchers who studied serum selenium 
levels  in animals fed with selenium deficient diet compared to animals fed with 
selenium adequate diet is that selenium deficiency resulted in an increase in plasma 
T4 and decrease in plasma T3 (34).  
The finding of this study and other studies about the relationships between 
selenium and (T4, T3 and TSH) can be explained as follows: 
The iodothyronine deiodinases types I, II and III regulate the activity of thyroid 
hormones via removal of specific iodine moieties from the precursor molecule T4. 
Type I deiodinase in the liver and the kidney is responsible for the peripheral 
conversion of T4 to T3. It is a selenoenzyme and so its activity is reduced in selenium 
deficiency leading to increases in plasma T4 and decreases in plasma T3. 
Type 2 deiodinase is expressed mainly in the pituitary, it is doubtful whether its 
activity is selenium dependent or not, but the high plasma T4 (as in selenium 
deficiency) inhibits its activity with the resultant inability of the pituitary to recognize 
the high free T4 due to the impaired intra pituitary conversion of T4 to T3. So, TSH 
will be normal or increased. 
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4.2. CONCLUSION 
 
This is the first study conducted in Sudan to explore selenium status in hypo and 
hyperthyroidism. 
The study concluded that: 
1- Significantly low serum selenium levels in hypothyroid patients confirm the 
possible implication of selenium deficiency in the causation of hypothyroidism as 
reported in the literature. 
2- Controlling hypothyroidism with thyroxine replacement may have a possible role 
in improving selenium deficiency; still this finding needs further exploration. 
3-  Inverse relationships were found between: (serum selenium and serum TSH) and 
(serum selenium and serum T4) confirming the role of selenium in thyroid 
hormones metabolism. 
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4.3. RECOMMENDATIONS 
 
1- Further studies spanning longer durations and involving other patients from 
different hospitals and different areas of Sudan are needed to consolidate the 
findings of this study. 
2- Efforts should be put on identifying the reference range of serum selenium in our 
home population in Sudan. 
3- Further studies that determine the prevalence of autoimmune thyroid disease in 
Sudan and to specifically evaluate selenium status in autoimmune thyroid disease 
are more valuable and thus needed. 
4- Longitudinal studies to explore the effect of treatment with thyroxine on serum 
selenium levels are also needed. 
5- Measurement of free thyroid hormones concentration should be performed in all 
samples submitted for thyroid function tests in KTH and should replace total 
hormones measurements. 
6- Introduction of thyroid antibodies measurements as complementary tests to those 
who are at great suspicion of having autoimmune thyroid disease. 
7- Protocols for introducing selenomethionine supplements to patients with 
autoimmune thyroid disease and monitoring the response by following the level of 
thyroid antibodies.  
8- Efforts should be made from the government on enrichment of the soil with both 
selenium and iodine to guard against the conditions arising from deficiency of both 
elements. 
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Appendix I 
 Selenium level in thyroid disease  
Questionnaire 
 Patients name:  ..................................................  
1. Age:          (1) 16-30yrs                  (2)>31-50yrs                   (3)>50yrs   
2. Sex:          (1) Male                        (2) Female                    
Disease identification: 
3. Case type:  
 (a) Known  case                                       (b) New case 
4. If known case, the diagnosis is:  
(a) Hypothyroidism                                  (b)Hyperthyroidism 
5. Regarding treatment:  
(a) On treatment                                                                                          
   Specify: ……………………………………….. 
Duration:             (a) weeks         (b) Months                   (c) years  
(b) Not on treatment   
(c) Was on treatment and stopped 
Specify, ………………………………………………………. 
Duration           (a) weeks            (b) Months                   (c) years  
6. If new case,                                                                                                        
Complain: ………………………………………………………………. 
Final diagnosis:                                                                                              
(a) Hypothyroid                      (b) Hyperthyroid                 (c ) Euthyroid  
7. Results of thyroid functions:                                                                            
(i) TSH value …..        a. high                        b. low                c. normal 
(ii) T4 value …..         a. high                        b. low                c. normal 
 (iii) T3 value ……       a. high                        b. low                c. normal 
8. Results of plasma selenium level  
Value:  ….          a. high                        b. low                c. normal 
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Appendix II 
Principle of atomic absorption 
Flame atomic absorption spectroscopy (F AAS) is a very common technique for 
detecting metals and metalloids in solid and aqueous samples. It is very reliable and 
simple to use. The technique is based on the fact that ground state metals absorb light 
at specific wavelengths. Metal ions in a solution are converted to atomic state by 
means of a flame. Light of the appropriate wavelength is supplied and the amount of 
light absorbed can be measured against a standard curve.  
The technique of (F AAS) requires a liquid sample to be aspirated, aerosolized, and 
mixed with combustible gases, such as; tcetylene and air or acetylene and nitrous 
oxide. The mixture is ignited in a flame whose temperature ranges from 2100 to 2800 
Qc. During combustion, atoms of the element of interest in the sample are reduced to 
free, unexcited ground state atoms, which absorb light at characteristic wavelengths. 
The characteristic wavelengths are element specific and accurate to 0.0 1-0.1nm. To 
provide element specific wavelengths, a light beam from a lamp whose cathode is 
made of the element being determined is passed through the flame. A device such as a 
photon multiplier can detect the amount of reduction of the light intensity due to 
absorption by the analyte, and this can be directly related to the amount of the element 
in the solution.  
 
 
